RPTX241220P7500
- 4.39
- 0.000.00%
Repare Therapeutics Newsroom
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
Repare Therapeutics Analyst Ratings
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating With $10 Price Target
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Repare Therapeutics Analyst Ratings
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Hold Rating on Repare Therapeutics Amidst Early Promising Clinical Results and Safety Concerns
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Repare Therapeutics Analyst Ratings